Brokerages expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to announce ($0.21) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from ($0.21) to ($0.20). Pieris Pharmaceuticals posted earnings of ($0.14) per share in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is scheduled to announce its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.84) to ($0.82). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.86) to ($0.83). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Pieris Pharmaceuticals.
Several equities research analysts recently issued reports on the company. BidaskClub downgraded Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 26th. HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th. Rodman & Renshaw assumed coverage on Pieris Pharmaceuticals in a research note on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, TheStreet downgraded Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research note on Monday, June 12th. Five equities research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has an average rating of “Buy” and an average target price of $8.25.
TRADEMARK VIOLATION WARNING: “Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.21 Per Share” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2887460/pieris-pharmaceuticals-inc-pirs-expected-to-post-earnings-of-0-21-per-share.html.
In other Pieris Pharmaceuticals news, insider Allan Reine acquired 65,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average cost of $4.82 per share, with a total value of $313,300.00. Following the purchase, the insider now owns 45,000 shares in the company, valued at $216,900. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James A. Geraghty acquired 10,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average cost of $4.82 per share, with a total value of $48,200.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $48,200. The disclosure for this purchase can be found here. 4.05% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC purchased a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $100,000. State of Wisconsin Investment Board purchased a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $132,000. The Manufacturers Life Insurance Company lifted its stake in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $162,000. Finally, Rhumbline Advisers purchased a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $184,000. 50.55% of the stock is owned by hedge funds and other institutional investors.
Pieris Pharmaceuticals (PIRS) traded down 1.47% during mid-day trading on Friday, reaching $5.35. The company’s stock had a trading volume of 192,019 shares. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $5.48. The firm has a 50-day moving average of $5.43 and a 200 day moving average of $2.55. The firm’s market capitalization is $237.05 million.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.